Celularity and Fountain Life have formed a strategic partnership to provide regenerative stem cell therapies at Fountain Life’s longevity centers in Florida, leveraging the state’s new law that permits physician-administered adult stem cell treatments without FDA IND approval.

This collaboration marks a significant step toward expanding patient access to innovative cellular therapies for orthopedic conditions, wound healing, and pain management under a regulated framework.

The Florida statute (§ 458.3245), effective July 1, 2025, authorizes licensed physicians to treat eligible patients with autologous or allogeneic adult stem cell products for specific indications, including orthopedics, wound care, and pain management, without requiring investigational new drug approval from the US Food and Drug Administration (FDA).

Fountain Life operates four state-of-the-art longevity centers across the US, including Naples and Lake Nona-Orlando in Florida, with a new center opening soon in Miami. These centers are equipped to deliver Celularity’s ethically sourced, placental-derived stem cell therapies in accordance with the new law.

Celularity, a pioneer in postpartum placental cell therapies, offers a broad pipeline of human placental-derived stem cells and mesenchymal stem cell-like candidates. These therapies are supported by extensive clinical data and are manufactured in Celularity’s FDA-registered, GMP-compliant facility in New Jersey. The company maintains a substantial inventory of investigational therapies ready for immediate physician-directed use.

Robert Hariri, CEO and chairman of Celularity, highlighted the company’s readiness to supply clinical-grade stem cells to partners like Fountain Life, praising Florida’s forward-thinking approach to advancing investigational stem cell treatments.

Dr. William Kapp, CEO and co-founder of Fountain Life, emphasized the company’s commitment to rigorous clinical standards and its alignment with Florida’s stringent sourcing criteria, noting Celularity’s proven ability to meet these requirements and provide advanced cellular therapeutics to members.